Results 111 to 120 of about 7,117 (221)

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience [PDF]

N/
Autore, Francesco, Bellesi, Silvia, Fresa, Alberto, Galli, Eugenio, Innocenti, Idanna, Laurenti, Luca, Mosca, Antonio, Sangiorgi, Eugenio, Stirparo, Luca, Tomasso, Annamaria   +9 more
core   +1 more source

Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report

eJHaem
The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable.
Anna Nikkarinen, Ingrid Glimelius
doaj   +1 more source

Inhibition of Bruton's Tyrosine Kinase Activity Attenuates Hemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats [PDF]

, 2023
Aimaretti, Eleonora, Alves, Gustavo Ferreira, Collino, Massimo   +2 more
core   +1 more source

Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma [PDF]

, 2017
Cerchione, Claudio, Ciancia, Giuseppe, DELLA PEPA, Roberta, DI PERNA, Maria, Giordano, Claudia, Intrieri, Mariano, Pane, Fabrizio, Picardi, Marco, Pugliese, Novella, Raimondo, Marta, Troncone, Giancarlo, Zacheo, Irene   +11 more
core   +1 more source

Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate [PDF]

Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate Acalabrutinib or 4-{8-Amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1- yl}-N-(pyridin-2-yl)benzamide is the active pharmaceutical ingredient (API) in the ...
Anonymous,
core   +1 more source

Outbreak of immediate-type hydrolyzed wheat protein allergy due to a facial soap in Japan [PDF]

, 2017
Aihara Michiko, Chinuki Yuko, Fukushima Atsuki, Fukutomi Yuma, Hide Michihiro, Ikezawa Zenro, Itagaki Yasuharu, Kato Zenichiro, Kishikawa Reiko, Matsunaga Kayoko, Morita Eishin, Nakamura Masashi, Noguchi Emiko, Saito Hirohisa, Sugiura Shin-ichi, Tanaka Hiroyuki, Teshima Reiko, Urisu Atsuo, Yagami Akiko, 野口 惠美子   +19 more
core   +2 more sources

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma [PDF]

, 2020
al., et, Bartlett, Nancy L., Cashen, Amanda, Edwin, Natasha, Ghobadi, Armin, Kahl, Brad, Mehta-Shah, Neha, Merryman, Reid W.   +7 more
core   +1 more source

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia [PDF]

, 2017
C. J. Owen, C. L. Toze, C. Shustik, I. Bence-Bruckler, R. Delage, S. Coutre   +5 more
core   +1 more source

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy [PDF]

, 2018
Coats, Josh, Collins, Graham P., Cross, Matthew, Dyer, Martin J. S., Eyre, Toby A., Follows, George, Fox, Christopher P., Hodson, Andrew, Iyengar, Sunil, Morley, Nick, Narat, Santosh, Walter, Harriet S.   +11 more
core   +3 more sources

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia. [PDF]

Future Oncol
Shadman M, Chanan-Khan A, Campbell D, Xue M, Massoudi M, Williams R, Yang K, Tam CS.   +7 more
europepmc   +1 more source